Featured Story | By Nick Paul Taylor Bristol Myers Squibb’s deucravacitinib has outperformed Amgen’s Otezla in a phase 3 clinical trial of patients with moderate to severe plaque psoriasis. The study linked deucravacitinib to improvements in symptom severity against two measures that served as the co-primary endpoints. read more |
| |
|---|
|
|  | For oncology CROs, the utilization of noninvasive optical imaging gives researchers an earlier indication of anti-cancer activity and valuable insight into the effects of new drugs. Our free white paper details its benefits and how this method can advance your drug program. Read more! |
Top Stories By Ben Adams Mayo Clinic neurologist David Knopman, M.D., has been kicked off an advisory committee assessing Biogen’s controversial Alzheimer’s hopeful aducanumab that's meeting later this week. read more By Amirah Al Idrus Jounce Therapeutics and its lead prospect took a hit Monday as its stopped enrollment in a phase 2 lung cancer trial. The company was testing the drug alongside Bristol Myers Squibb’s Yervoy in patients with non-small cell lung cancer, but an early look at the data showed the combo was unlikely to succeed. read more Sponsored By: WCG Are you looking to optimize your site’s patient recruitment advertising dollars? WCG’s experienced team of patient recruitment experts can help your site efficiently use your advertising funds by creating customized recruitment campaigns for any of your studies, and we’ve also curated a list of best practices to ensure your spend sees the best ROI. read more By Nick Paul Taylor FDA officials are pushing back against an executive order that will make it easier for President Donald Trump to fire federal employees, according to a report in Politico. Patrizia Cavazzoni, the acting head of the FDA’s drug center, is reportedly among the top officials to have raised concerns about Trump’s executive order. read more By Amirah Al Idrus China’s Clover Biopharma is getting another boost as it gears up for a global, pivotal trial of its COVID-19 vaccine. CEPI is adding $258.5 million to a deal the partners initially struck in April this year, which will see the candidate through a phase 2/3 study and licensure in China and other countries. read more By Amirah Al Idrus Aurinia and its dry eye drug started 2019 with a mixed bag of data from a head-to-head trial with Allergan’s blockbuster Restasis. Now, it’s unveiling results from a different trial—and they’re definitely not mixed. The company is abandoning the dry eye program after it failed to beat placebo at helping patients produce more tears. read more By Rae Ellen Bichell, Kaiser Health News In normal times, these researchers study stem cells and muscular dystrophy. Now, they are on the front lines against potential COVID-19 outbreaks on a campus with more than 23,000 undergraduates. read more Resources Sponsored By: AmerisourceBergen How pharma's supply chain partners are paving the way for coronavirus therapies. Sponsored By: Lonza Liquid-filled hard capsule formulations offer unique options for the manufacture and dosing of highly potent actives. Sponsored By: Thermo Fisher Scientific Anticipate early development challenges to avoid rework and costs. Sponsored By: Cytiva Accelerating the production of viral-vector based therapy requires both understanding of strategies to address viral vector manufacturing and how to select the most cost-effective solution for your therapeutic. Read more in this article. Sponsored by: LexisNexis Risk Solutions Get insights into healthcare decision-makers networks. Sponsored By: Veeva Learn how to plan immersive digital event experiences Sponsored by: Aldevron Gene and cell therapy organizations are asked to balance the need for rapid clinical progression and stringent quality expectations throughout development. In this document, Aldevron provides an in-depth look at preparing for plasmid manufacturing based on our years of experience. Sponsored By: Elligo Health Research® Understanding the Challenges COVID-19 Pediatric Clinical Trials Face | White Paper Sponsored By: Outer Edge Technology A sound Cloud Strategy provides the flexibility and tools businesses need to quickly adapt and operate securely in an ever-changing remote work environment. Learn how your company can cost-effectively empower its employees to be productive and secure while working remotely. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Cascade Chemistry, API CDMO Struggling with complex chemistry to get APIs for clinical trials? Find out what to look for in an API CDMO partner to gain expertise and speed that lead to success. Sponsored by: Catalent Learn about proven strategies for a successful product launch, including cross-functional team collaboration, risk management and using the right project management tools. Sponsored by: Catalent This eBook provides insights on key approaches and considerations for preparing your drug development program for long-term success. Sponsored by: Catalent In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site. Sponsored by: Formedix Learn how to save time and reduce costs and complexity by streamlining the clinical trial process. Sponsored by: Outer Edge Technology Cybercriminals Are Actively Exploiting The Coronavirus Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become The Next Ransomware Headline -- Make These Changes Now! Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
